The role of therapeutic drug monitoring in the treatment of cytomegalovirus disease in kidney transplantation-Reference-Cited by-同舟云学术

The role of therapeutic drug monitoring in the treatment of cytomegalovirus disease in kidney transplantation

Published:2012-09-30 Issue:6 Volume:45 Page:1809-1813
ISSN:0301-1623
Container-title:International Urology and Nephrology
language:en
Short-container-title:Int Urol Nephrol

Author:

Bedino Giulia,Esposito Pasquale,Bosio Francesca,Corradetti Valeria,Valsania Teresa,Rocca Chiara,Pattonieri Eleonora Francesca,Gregorini Marilena,Rampino Teresa,Dal Canton Antonio

Publisher

Springer Science and Business Media LLC

Subject

Urology,Nephrology

Link

http://link.springer.com/content/pdf/10.1007/s11255-012-0293-y.pdf

Reference20 articles.

1. San Juan R, Aguado JM, Lumbreras C et al (2007) Incidence, clinical characteristics and risk factors of late infection in solid organ transplant recipients: data from the RESITRA study group. Am J Transpl 7(4):964–971

2. Rubin RH (1990) Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis 12(Suppl 7):S754–S766

3. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB et al (1992) Simptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 53(1):68–72

4. Lumbreras C, Otero JR, Herrero JA et al (1993) Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies. Antimicrob Agents Chemother 37(11):2490–2492

5. Hart GD, Paya CV (2001) Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 11(2):73–81

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evidence supporting the use of therapeutic drug monitoring of ganciclovir in transplantation;Current Opinion in Infectious Diseases;2023-09-19

2. Comparison of Three Renal Function Formulas for Ganciclovir/Valganciclovir Dose Individualization in CMV-Infected Solid Organ Transplantation Patients Using a Population Approach;Clinical Pharmacokinetics;2023-05-04

3. Optimizing ganciclovir and valganciclovir dosing regimens in pediatric patients with cytomegalovirus infection: a spotlight on therapeutic drug monitoring;Expert Review of Clinical Pharmacology;2023-02-23

4. Optimizing Antiviral Dosing for HSV and CMV Treatment in Immunocompromised Patients;Pharmaceutics;2023-01-03

5. Assessment of alteration in antiviral plasma concentration across dialysis days: computational and analytical study;Bioanalysis;2022-12